Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
about
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsInfections in myelodysplastic syndromesMyelodysplastic syndromes: what do hospitalists need to know?Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromesAcquired myelodysplasia or myelodysplastic syndrome: clearing the fogMyelodysplastic syndromes: the role of the immune system in pathogenesis.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromesLow NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cellsCD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality.Mature natural killer cells reset their responsiveness when exposed to an altered MHC environmentRecognition of tumors by the innate immune system and natural killer cells.Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.Biology of BM failure syndromes: role of microenvironment and niches.Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.Biology of the bone marrow microenvironment and myelodysplastic syndromes.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemiaThalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cellsNK cell receptors and their ligands in leukemia.Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T CellsEffect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Immune alterations in untreated and treated myelodysplastic syndrome.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?Natural killer cell immune escape in acute myeloid leukemia.NK cells: key to success of DC-based cancer vaccines?Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
P2860
Q26746104-56A96C90-DE9B-49E8-9C20-81CFA163F1AAQ26751011-4D70085D-ECDC-4D76-8987-22E49F0096C9Q26859275-618EC9C0-F31C-41E0-BAB0-0BFB5CE5DEADQ27011372-E516710D-3A3A-4CC1-A9B5-BF58F06D231AQ27015288-8BB52241-F868-45BE-A713-715DDCC45F42Q28662217-9F8D1354-7E2B-4646-A4D2-C3650AD710D3Q33351527-26E1AD3B-50AC-41D0-A281-0263FA77C421Q33397165-FBC81BAD-3198-4137-A11B-62BA78BFB3DEQ33468660-172AD125-E4BC-4813-BAD5-AAC25A2435FCQ33584049-BE81FE0A-BFDF-4C68-982D-68BDB8563552Q33585293-AE8AF123-9860-44A4-A74A-843E0CB1ABD0Q33595548-338042CB-923E-4F53-BF09-B1C56C6E0F92Q33659992-08B54ABA-4ABF-4478-B29F-7039EE9094CDQ34161567-CCF57F36-87F9-436D-B69D-F324C330F599Q34496462-2943D2AF-3BCF-48C4-81F3-B7EA6C9F273FQ34510880-9B92045F-858A-425E-9864-C558CAE4E8E5Q35208414-7C3D1F56-65DE-4E56-AF74-AC71A61AEE77Q35458400-7BB73167-AE1B-4B8B-BD38-F31C1309BBD3Q35568527-7D300ED2-9477-4238-99AE-6D5540426CCAQ35571031-E0BD95C8-4C07-401D-9667-E0921AE21E8CQ36026855-0FB424EC-9CEF-495C-B11C-7278E76DAEC1Q36056594-7BB45813-5A88-4057-A19E-D1D0C9452821Q36201068-9C335860-7AF5-431D-808F-9890837CDD22Q36498399-A593A201-F829-41AD-9108-B46558F7525FQ36544042-1466F647-F81D-4CEB-B4D1-270FDE15E6EAQ36772346-98C0714C-20CA-4946-9AAC-423598C0C1BAQ36965455-55A2AFDD-2987-4D04-BA12-65A9DEE37080Q36969858-CCFB096E-CA9E-4A5C-9A00-E6F4895466C8Q37018656-BF380B1E-5AF4-4EC8-BE77-12B3439038FCQ37146038-134AC748-5521-4BC5-BF78-7D7AFD0D6EE4Q37303329-CFED8AEC-3910-412D-BA35-5DCBCB64215BQ37317299-1DBF8FD6-3F86-4929-8C27-8CF57200E204Q37779043-8896054F-4FA5-46F5-9B90-4E8AD44C4B60Q37854701-5F27A407-DDC5-4618-AD34-0688E2A3DC2AQ37864686-D2C4AC71-47A2-40D7-8F07-AC547E2A1C8EQ37885284-085C06A9-63CC-4DEB-BAE7-75B9DE980432Q37980495-6DA1F02B-DF5D-49D1-8CD0-50CBB7CB5D38Q37996816-C67865DE-07D4-449C-A679-1522E69EB7ABQ38036202-E913003A-2210-4FA1-823B-F62FF228CBA1Q38037118-E52D2A6A-720F-4FC7-931B-99C42DEC95EB
P2860
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@ast
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@en
type
label
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@ast
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@en
prefLabel
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@ast
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@en
P2093
P2860
P1433
P1476
Reduced natural killer (NK) fu ...... on of activating NK receptors.
@en
P2093
Alan F List
Dana E Rollison
David Boulware
Helmut R Salih
Jeffrey S Painter
Jianxiang Zou
Julie Y Djeu
P2860
P304
P356
10.1182/BLOOD-2006-07-035519
P407
P577
2007-03-06T00:00:00Z